

SCIENTIFIC PROGRAM

DAY 1		16TH AUGUST 2019	
TIME	TOPIC	SPEAKER (S)	CHAIR (S)
05:00 – 06:10 PM	Abstract presentation (7 selected oral from the EHA/ASH/ASCO)		Dr. Sadashivudu Gundeti Dr. Mathew Thomas
	TITLE	PRESENTER	
	1.E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma 2.Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1):: results of the AML study group 3.The first-in-class anti-cd47 antibody Hu5F9-G4 is active and well tolerated alone or in combination with azacitidine in AML and MDS patients: initial phase 1b results 4. Combination therapy using Asciminib plus Imatinib in patients with chronic myeloid leukemia: results from a phase 1 study 5. Venetoclax in combination with hypomethylating agents Induces rapid, deep, and durable responses in patients with AML ineligible for intensive therapy 6. IL7R expression predicts T-ALL sensitivity to JAK inhibitors regardless of IL7R/JAK/STAT mutational status 7. Enasidenib is highly active in previously untreated IDH2 mutant AML: early results from the BEAT AML master trial	1.Dr Ranjit Sahoo 2.Dr Gaurav Prakash 3.Dr Lingaraj Nayak 4.Dr Chandran Nair 5.Dr Smitha Saldahna 6.Dr Nikita Mehra 7.Dr Deepa Philip	
06:10 -06:25 PM	Coffee break		
06:25 – 07:00 PM	HCC Data Presentation		
	1. AML	Dr Deepam Pushpam	Dr. Tulika Seth
	2. ALL	Dr Hasmukh Jain	Dr. Loknath D
	3. APL	Dr Chepsy Phillip	Dr Boben Thomas
07:00 -08:00 PM	Prospective study proposals from the HCC sites – 6 concepts (5+5 minutes) Experts: Dr Hari Menon, Dr.Govind Babu & other international experts		
08:00 – 09:00 PM	Executive meeting		
DAY 2		17TH AUGUST 2019	
TIME	TOPIC	SPEAKER (S)	
07:55-08:00 AM	Welcome and Introduction		
SESSION 1:	Acute Lymphoblastic Leukemia		Chairpersons Dr Tapan Saikia, Dr Subhash Varma
08:00 - 08:30 AM	Overview of recent advances in ALL	Dr. Charles Mullighan	

08:30 - 08:50 AM	Understanding ETP- ALL: Biology and its implications	Dr. Manju Sengar	
08:50 - 09:10 AM	Management of AYA - which way to go?	Dr. Prasanth Ganesan	
09:10- 10:10 AM	Multi-disciplinary team discussion on ALL (Adult ALL including both Ph+ve and Ph-ve)	Dr. Charles Mullighan Dr. Jayachandran Dr. Anu Korula Dr. Anita Chopra Dr. Kunal Sehgal Dr. Punit Jain	Lead discussant - Dr. Manju Sengar
10:10-10:20 AM	Coffee Break		
SESSION 2:	Acute Myeloid Leukemia		Chairpersons Dr Govind Babu, Dr Velu Nair
10:20 - 10:50 AM	Recent advances in biology of AML	Dr. Harry Erba	
10:50 - 11:30 AM	Evolving landscape of de-novo AML therapy	Dr Farhad Ravandi	
11:30 - 12:00 PM	Approach to elderly Acute Myeloid Leukemia	Dr. Harry Erba	
12:00 - 01:00 PM	Multi-disciplinary team discussion on AML	Dr. Harry Erba Dr Farhad Ravandi Dr Sameer Melinkeri Dr. Mayur Parihar Dr. Smita Kayal Dr. Poonkuzhali Balasubramaniam	Lead discussant - Dr. Vikram Mathews
01:00 - 01:30 PM	Lunch		
SESSION 3:	Acute Promyelocytic Leukemia		Chairpersons Dr Biju George Dr Atul Sharma
01:30 - 2:15 PM	Acute Promyelocytic Leukemia: Current understanding of biology and management	Dr. Harry Iland	
SESSION 4:	Multiple Myeloma		Chairpersons Dr Lalit Kumar Dr. Neelam Varma
02:15 - 03:00 PM	Recent advances in the of Multiple Myeloma	Dr. Sundar Jagannath	
03:00 - 03:20 PM	How to treat newly diagnosed multiple myeloma	Dr. Anup Devasia	
03:20 - 04:20 PM	Multi-disciplinary team discussion on Multiple Myeloma	Dr. Sundar Jagannath Dr. Sharat Damodar Dr. Ritu Gupta Dr. Y. Uday Dr. Anil Handoo Dr. Arun Kumar A	Lead discussant- Dr. Pankaj Malhotra
04:20 - 04:30 PM	Coffee Break		
SESSION 5:	Chronic Myeloid Leukemia		Chairpersons Dr. Hemant Malhotra Dr. Rajiv Kumar
04:30 - 05:00 PM	Consensus and controversies in front-line therapy of CML	Dr. Timothy Hughes	
05:00 - 05:20 PM	Toxicities of TKI: Compare and contrast	Dr. Dinesh Bhurani	
05:20 - 05:50 PM	Treatment free remission- is it ready for clinics	Dr. Timothy Hughes	

05:50 – 06:50 PM	Multi-disciplinary team discussion on CML	Dr. Timothy Hughes Dr. Hari Menon Dr. P.G.Subramanian Dr. Kundan Mishra Dr. Aby Abraham Dr. Sanjeevan Sharma Dr Rishi Dhawan	Lead discussant- Dr. Abhay Bhawe
07:00 - 08:00 PM	Dinner		
DAY 3	18TH AUGUST 2019		
TIME	TOPIC	SPEAKER (S)	CHAIR (S)
SESSION 6:	Myelodysplastic Syndrome		Chairpersons Dr Karthikeyan Dr Abhay Bhawe
08:00 -08:20 AM	MDS: Management of Low risk MDS	Dr Jina Bhattacharya	
08:20 - 08.50 AM	Management of high-risk MDS and secondary AML	Dr. Austin Kulasekaraj	
08:50-09:45 AM	Multi-disciplinary team discussion on MDS	Dr. Austin Kulasekaraj Dr Mayur Parihar Dr Anup Devasia Dr Neeraj Sidharthan Dr Farhad Ravandi Dr Prantar Chakrabarti	Lead discussant- Dr. Biju George
09:45-10:00 AM	Coffee Break		
SESSION 7:	MRD / Recent Advances in Hematology		Chairpersons Dr. Sumeet Gujral Dr K. Pavithran
10:00- 10:30 AM	MRD in ALL: Current status and recent advances	Dr. Charles Mullighan	
10:30 - 10:45 AM	Role of next generation sequencing in myeloid malignancies: Laboratory perspective	Dr. Nikhil Patkar	
10:45 – 11:00 AM	Role of next generation sequencing in myeloid malignancies: Clinicians perspective	Dr. Harry Erba	
11:00 – 11:15 AM	MRD in Myeloma: Laboratory perspective	Dr.Prashant Tembhare	
11:15 – 11:30 AM	MRD in Myeloma: Clinicians perspective	Dr. Sundar Jagannath	
SESSION 8	Breakthrough and recently approved drugs		Chairpersons Dr Manoj Unni Dr Rahul Bhargava
11:30-11:50 AM	Bcl2 inhibitors and hematology	Dr. Atul Sharma	
11:50 - 12:10 PM	Antibody based immunotherapy in hematology	Dr Reetu Jain	
SESSION 9:	Ask the expert session		
12:10 – 01:45 PM	Moderators Dr. Rajan Kapoor Dr. Vikram Mathews		
01:45 – 01:55 PM	Vote of Thanks	Dr. Manju Sengar	

01:55 PM ONWARD	LUNCH		
POSTER JUDGES	Dr Sandeep Jasooja Dr Santhosh KD Dr Avinash Bonda	Results will be announced before lunch	